Market Research Report
The Pacemaker Global Supply Chain: Fifty-three Suppliers, Twelve Countries, Fifteen Product Classes
|Published by||Greystone Research Associates||Product code||960349|
Delivery time: 1-2 business days
|The Pacemaker Global Supply Chain: Fifty-three Suppliers, Twelve Countries, Fifteen Product Classes|
|Published: September 14, 2020||Content info:||
Cardiac pacing has evolved considerably over the years from its initial introduction as a lifesaving measure by asynchronous ventricular pacing. Pitfalls of ventricular-only pacing were recognized relatively early, which led to the introduction of atrioventricular (AV) synchronous pacing that was subjected to rigorous clinical studies. Cardiovascular implantable electronic device (CIED) is a term that encompasses pacemakers for arrhythmia treatment, implantable cardioverter defibrillators (ICDs) for arrhythmia management, and cardiac resynchronization therapy (CRT) devices for systolic dysfunction with conduction delays. Cardiac arrhythmias have an estimated prevalence of 14.4 million patients in the United States, and they account for approximately 40,700 deaths annually.1 As the indications for device placement continue to expand and with data supportive of device placement compared to medical therapy well established, CIEDs are becoming common in our patient population.Approximately one million patients worldwide receive a pacemaker or implantable cardioverter defibrillator (ICD) each year.